↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
argenx adds anti-CD122 asset, diversifying beyond Fc receptors into IL-2 modulation with orphan dermatology pathway.
$2.1 billion
in 2025 revenue on VYVGART for myasthenia gravis and…
60 days
signaling integration speed
$47 million
market capitalization at last close and the limited pool…
argenx commenced a tender offer to acquire Forte Biosciences, the clinical-stage developer advancing FB102, a proprietary anti-CD122 monoclonal antibody. The transaction marks argenx's expansion beyond its Fc receptor platform into IL-2 pathway modulation, a mechanism with applications across autoimmune and inflammatory indications where current therapies show incomplete efficacy.
Forte Biosciences entered clinical development with FB102 targeting CD122, the beta subunit of the IL-2 receptor complex expressed on effector T cells and NK cells. The asset completed Phase 1 safety studies and moved into mid-stage trials for atopic dermatitis and alopecia areata. argenx, which built $2.1 billion in 2025 revenue on VYVGART for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has been methodical in acquiring late-preclinical and early-clinical assets that address shared immunological targets without cannibalizing existing indication pathways. The tender structure suggests argenx valued Forte's IP estate and clinical data package over any near-term commercial timeline.
The acquisition extends argenx's therapeutic reach into dermatology and autoimmune hair loss, indications where payer familiarity with monoclonal antibodies has improved but competitive pressure from Sanofi, Regeneron, and Eli Lilly remains concentrated in IL-4, IL-13, and JAK pathways. CD122 inhibition offers a differentiated mechanism, potentially allowing argenx to avoid head-to-head comparisons in crowded categories while retaining access to specialist prescriber networks already adopting VYVGART in neuromuscular disease. The FDA granted Forte orphan designation for alopecia areata in 2022, which carries seven years of market exclusivity if FB102 reaches approval. For argenx, this represents a hedge against VYVGART biosimilar erosion expected after 2030 and a second commercial franchise outside neurology.
Allocators should monitor the tender close date and any SEC filings revealing per-share consideration or equity rollovers for Forte management. argenx typically structures these deals with modest upfront cash and milestone-based payouts tied to Phase 2 readouts, preserving balance sheet optionality while aligning seller incentives. Clinical trial databases should reflect updated sponsor listings for FB102 studies within 60 days, signaling integration speed. Any pivot in trial design or endpoint selection will indicate whether argenx views FB102 as a standalone asset or a combination candidate with VYVGART in overlapping autoimmune settings.
The tender opened without a competing bid, which is consistent with Forte's $47 million market capitalization at last close and the limited pool of acquirers with both autoimmune franchises and capital for clinical-stage antibodies.
Branded by POPS4 · proof in 60 seconds
For the principal
Consider whether argenx's diversification into dermatology pipelines warrants rebalancing European biotech exposure away from single-asset neurology names.
For the operator
Track FB102 Phase 2 data timing and any combination trial announcements with VYVGART for autoimmune overlap indications.
For the house
Huang Goodman maintains argenx in named European biotech sleeve; no near-term allocation change pending clinical milestone clarity.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.